A detailed history of Charles Schwab Investment Management Inc transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 129,761 shares of PYXS stock, worth $219,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129,761
Previous 129,761 -0.0%
Holding current value
$219,296
Previous $429,000 10.96%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$3.06 - $5.58 $352,625 - $643,022
115,237 Added 793.42%
129,761 $429,000
Q1 2024

May 08, 2024

BUY
$2.03 - $6.59 $29,483 - $95,713
14,524 New
14,524 $61,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $3.03 $33,349 - $53,749
17,739 New
17,739 $35,000
Q2 2022

Aug 15, 2022

SELL
$2.02 - $4.53 $46,649 - $104,615
-23,094 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$8.39 - $13.64 $193,758 - $315,002
23,094 New
23,094 $254,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $59.3M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.